Alberta Research Council Incorporated

Integris Baptist Medical Center, Inc.

Isodiagnostika Inc.

Other

Isotechnika Inc.

Integris Baptist Medical Ctr.

Alberta Research Council Edmonton

Andrew J Malcolm

A Heather Good

David K Cooper

Randall W Yatscoff

S Selvaraj Naicker

Selvaraj A Naicker

David Kc Cooper

Heather A Good

This invention relates to the production of polyclonal and monoclonal antibodies to specific regions of cyclosporine (CSA) and/or CSA metabolites/derivatives. The reactivity of these polyclonal and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of CSA and/or CSA metabolites. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Cyclosporine or CSA metabolite conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the CSA or CSA metabolite molecule. By determining the specific binding region of a particular antibody, immunoassays which are capable of distinguishing between the parent molecule, active metabolites, inactive metabolites and other structurally similar immunosuppressant compounds are developed. The use of divinyl sulfone (DVS) as the linker arm molecule for forming cyclosporine and cyclosporine metabolite protein conjugate immunogens is described.

Immunoassay method for measuring a cyclosporine and its metabolites

This invention relates to the production of polyclonal and monoclonal antibodies to specific sites of rapamycin (Sirolimus). The reactivity of these poly and monoclonal antibodies make them particularly useful for immunoassays for therapeutic drug monitoring (TDM). These immunoassays or TDM kits may include polyclonal or monoclonal antibodies to specific sites of rapamycin. These kits may also include various combinations of polyclonal antibodies, polyclonal and monoclonal antibodies or a panel of monoclonal antibodies. Rapamycin conjugate immunogens are prepared for the immunization of a host animal to produce antibodies directed against specific regions of the rapamycin molecule. By determining the specific binding region of particular antibody, immunoassays which are capable of distinguishing between the parent molecule, active metabolites, inactive metabolites and other structurally similar immunosuppressant compounds are developed. The use of divinyl sulfone (DVS) as the linker arm molecule for forming rapamycin-protein conjugate immunogens is described. DVS-linked rapamycin-protein conjugates were found to elicit antibodies with greater specificity to the rapamycin molecule than succinate linked conjugates.

Method for production of antibodies to specific sites of rapamycin

Antibodies to specific regions of cyclosporine related compounds

Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.

Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients

This invention provides compositions comprising an oligosaccharide of,serotype,useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these,serotype,oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.

Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides

The invention provides immunogenic oligosaccharide compositions and methods of making and using them. In particular, the compositions comprise oligosaccharides covalently coupled to carrier protein, wherein the resultant conjugate has been shown to contain specific immunogenic epitopes and elicits a protectively immunogenic response.

Immunogenic oligosaccharide compositions

Compositions for attenuating antibody- mediated xenograft rejection in

The invention provides compositions comprising an oligosaccharide of S. pneumoniae serotype 8 useful for stimulating an immune response to an antigen, methods of providing protective immunization against a bacterial pathogen using these compositions, methods of augmenting an immunogenic response to an antigen by administering these S. pneumoniae serotype 8 oligosaccharide compositions along with the antigen, and methods of making the immunostimulatory compositions described above.

Immunostimulating activity of streptococcus pneumoniae serotype 8

Immunostimulating activity of Streptococcus pneumoniae serotype 8

Immonogenic oligosaccharide compositions

Antibody-mediated xenograft rejection is attenuated by parenterally administering a xenoantibody-inhibiting amount of an identified carbohydrate xenoantigen to the recipient shortly before graft revascularization and thereafter.

Growing community of inventors

Edmonton, Canada

Andrew J Malcolm